The strongest effect was seen in UMC-11 cells, where MeV-SCD monotherapy at MOI 0.25 reduced the remaining tumor cell mass to ~60%, while the addition of the prodrug led to less than 25% remaining viable tumor cells in comparison to MOCK-treated controls. Here, SCD is linked to neoplasm.